Over 10,000 women enrolled at over 1,000 sites

The largest randomised adjuvant breast cancer treatment trial ever conducted

TAILORx was independently led by ECOG-ACRIN Cancer Research Group with sponsorship from the National Cancer Institute. Participating cancer research groups included the Alliance for Clinical Trials in Oncology, NCIC-Clinical Trials Group, NRG Oncology, and SWOG.


Read the article on NEJM

TAILORX: TRANSFORMING THE TREATMENT OF BREAST CANCER

The TAILORx trial followed over 10,000 women with early breast cancer for an average of 9 years. Over 1,000 trial sites in 6 countries participated.

The Oncotype DX Breast Recurrence Score test is the only genomic test proven to predict a patient's individual benefit of chemotherapy.


Learn more about the test
REFERENCES

  1. Sparano et al. N Engl J Med. 2015.
  2. Sparano et al. N Engl J Med. 2018.

NIH = National Institute of Health

RS = Recurrence Score result

TAILORx = A Clinical Trial Assigning IndividuaLized Options for Treatment (Rx)

The TAILORx trial was conducted independently by the ECOG-ACRIN Cancer Research Group.

Making cancer care smarter.™